Pre-made Drozitumab benchmark antibody ( Whole mAb, anti-TNFRSF10B/TRAIL-R2 therapeutic antibody, Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Drozitumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Drozitumab is a human monoclonal antibody in development for the treatment of cancers.[1] It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.[2] Drozitumab was developed by Genentech.
| Products Name (INN Index) | Pre-Made Drozitumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody |
|---|---|
| INN Name | Drozitumab |
| Target | TNFRSF10B |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 4od2:BA |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Genentech |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Chondrosarcoma,Colorectal cancer,Non-Hodgkin's lymphoma,Non-small cell lung cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TNFRSF10B |
| Package |
